US biopharmaceutical company, AbbVie, has completed the acquisition of Syndesi Therapeutics, a Belgium-based clinical stage biotechnology company. AbbVie will pay Syndesi shareholders a US$130m upfront with another US$870m in potential additional payments contingent on reaching predetermined milestones. The acquisition will help expand AbbVie’s neuroscience portfolio, giving it access to Syndesi’s portfolio of modulators of the synaptic vesicle protein…
©2023 All rights reserved LaingBuisson 
